GoodRx will offer the GLP-1s for $499 a month, the lowest-ever out-of-pocket cost for the weight-loss medications.

Interestingly, Wall Street firms largely believe the former will playout in the long run. According to The Wall Street Journal, the consensus rating on Goodrx Holdings currently sits at “overweight” with price targets going as high as $7.0, indicating potential “upside” of another 35% from here.